12/30/2017: Microbiome on tumor development and immunotherapy effect (Belkaid Y & Hand TW. Cell 2014; 157: 121-41; Mayer EA et al. J Neurosci 2014: 34: 15490-6.; Morris G et al. Mol Neurobiol 2017: 54: 4432-51; Sivan A et al. Science: 2015; 350:1084-9; Vétizou M et al. Science 2015; 350:1079-84)
12/24/2017: Combination of Alisertin, an aurora kinase A inhibitor and TAK-228 in solid tumors (Diamond J et al. ScienceDaily, 1 November 2017. <www.sciencedaily.com/releases/2017/11/171101130336.htm>)
2017/12/23: New promising treatment for refractory myeloma: CAR-T therapy (Berdeja JG et al ASH Meeting 2017; Session 652 Myeloma oral presentation. Fan F et al. J Clin Onc 2017; 35 (18_suppl) : LBA3001)
12/17/2017: Yescarta benefited refractory lymphoma patients (https://www.fiercepharma.com/pharma/ash-long-term-car-t-data-looks-good-for-gilead-but-good-enough-to-top-its-rivals)
12/16/2017: Nivolumab plus Ipilimumab vs Sunitinib alone as first-line therapy for metastatic renal cell carcinoma (Tannir EB et al. ESMO 2017 Congress. abstr LBA5)
12/10/2017: Using tocilizumab to manage adverse effects from anti-PD-1 drugs (Stroud CR et al. IASLC Multidisciplinary Sym Thoracic Onc 2017; abate OA03.05)
12/7/2017: Oral bacterium in association with esophageal cancer (Peters BA et al. Cancer Res 2017; 77 (23): 6777 DOI: 10.1158/0008-5472.CAN-17-1296)
12/3/2017: FDA granted market approval for FoundationOne’ NGS in vitro diagnostic test (https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587273.htm)
12/2/2017: Eryaspase plus chemotherapy benefits metastatic pancreatic cancer (Hammel P et al. Annal Onc 2017: 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369)
11/26/2017: Biomarkers used to predict recurrence and survival after treatment for localized lung cancer (Chaudhry A et al. Am Soc Radia Onc Ann Meeting 2017, abstr 2)
11/25/2017: Experimental “nano-chemo” particle to treat bladder cancer (Kates M et al. Clin Cancer Res 2017; DOI: 10.1158/1078-0432.CCR-17-1082)
11/19/2017: Anti-inflammatory drug canakinumab may reduce incident lung cancer (Ridker PM et al. Lancet 2017; 390:1833-42)
11/18/2017: Abiraterone or docetaxel: which is optimal for hormone-sensitive high-risk prostate cancer? (Sydes MR et al. 2017 ESMO CongressAbstr LBA31; Vale CR. 2017 ESMO Congress abstr LBA33)
11/12/2017: Germline mutations in sporadic pancreatic cancer patients (Shindo K et al. J Clin Onc 2017; 35:3382-90)
11/11/2017: Amyloidosis (Gertz MA et al. 2016 ASH Meeting abstr 644)
11/5/2017: Adjuvant combination therapy for stage III BRAF-mutant melanoma doubles relapse-free survival (Hauschild A. ESMO 2017 Congress Abstract LBA6)
11/4/2017: PD-L1 inhibitor，durvalumab, used after chemoradiation for non-small cell lung cancer (Antonia SJ et al. N Engl J Med 2017; doi: 10.1056/NEJMoa1709937)
10/30/2017: Association of vitamin B supplement and increased lung cancer incidence (Brasky TM et al. J Clin Onc 2017; 35: 3440-8)
10/21/2017: Luspatercept in treatment of lower-risk myelodysplastic syndrome (Platzbecker U wt al. Lancet Onc 2017:18; 1338-47)
10/15/2017: An effective PARP inhibitor in BRCA-mutated breast cancer (Turner NC et al. 2017 ASCO Ann Meeting. Abstr 1007; de Bono J et al Cancer Discove 2017; 7: 620-9)
10/14/2017: Effect of Nivolumab versus Ipilimumab in resected stage III or IV melanoma (Weber J et al. N Engl J Med September 10, 2017DOI: 10.1056/NEJMoa1709030)
10/8/2017: Impact of neo-adjuant chemotherapy followed by surgical resection on survival in gastric or GEJ cancer with limited metastases (Al-Batran S-E, et al. JAMA Onc 2017; 3: 1237-44)
10/7/2017: Retroperitoneal exploration improves survival in optimally debulked ovarian cancer (Rungruang BJ et al. Cancer 2017; doi:10.1002/cncr.30414)
10/1/2017: Preoperative TDM-1 for 12 weeks in HER-2 positive breast cancer achieved significant pathologic complete response (Harbeck N et al. J Clin Onc 2017:35:3046-54)
9/30/2017: 177-Lu-Dotate therapy for neuroendocrine tumors (Strosberg J et al. N Engl J Med 2017; 375: 125-35)
9/24/2017: Circadian rhythm disruption linked to cancer risk (Davis S et al. J Natl Cancer Inst 2001; 93:1557-62; Bhatti P et al. Lancet Oncol 2007; 8:1065-6; Bhatti P. et al. Occup Environ Med 2016; 73:537-44; Papagiannakopoulos T et al. Cell Metab 2016; 24: 324-31)
9/23/2017: MONARCH 2: Abemaciclib and fulvestrant combination in breast cancer patients (Sledge GW et al J Clino Onc 2017; 35: 2875-84)
9/17/2017: Nivolumab is active in advanced hepatocellular carcinoma (El-Khoueiry AB et al. Lancet 2017; 382:2492-502)
9/16/2017: Radiation improves outcome in metastatic right-sided colon cancer (van Hazel G et al. ESMO World Congress on GI cancer 2017; Abstr LBA-006)
9/10/2017: Labetuzumab may provide benefit to relapsed/refractory metastatic colorectal cancer (Dotan E et al. J Clin Oncol. 2017 Aug 17. [Epub ahead of print] doi: 10.1200/JCO.2017.73.9011)
9/9/2017: Osimertinib improves outcome of lung cancer patients with EGFR mutation (Nei K et al. J Clin Onc 2017; 35: suppl abstr 9017)
9/3/2017: Aldoxorubicin improves outcome in relapsed/refractory sarcoma (Chawla SP et al. J Clin Onc 2017; 35 (suppl abstr 11000))
9/2/2017: Combination therapy effective in melanoma patients with brain metastases (Davies MA et al. ASCO 2017 Ann Meeting Abstr 9506; Tawbi HA et al. ASCO 2017 Ann Meeting Abstr 9507; Long GV et al. ASCO 2017 Ann Meeting Abstr 9508)
8/27/2017: Lenolidomide and anti-CD19 monoclonal antibody MOR208 has activity against DLBCL (Salles R et al. Hemat Oncol 2017; 35: suppl 51-52. DOI )
8/26/2017: Perioperative chemotherapy improves survival of gastric and GE junction cancers (Al-Bartran SE et al. J Clin Oncol 2017; 35: suppl; abstr 4004)
8/20/2017: Plasmid EBV DNA screening for nasopharyngeal cancer (Chan, KC et al. N Engl J Med 2017; 377:513-22)
8/19/2017: Dabrafenib/Trametinib combination approved by FDA for BRAF+ NSCLC (Planchard D et al. J clin Onc 2016; 34 (suppl; absr 107); Lancet Oncol 2016; 17:984-93)
8/13/2017: Three months adjuvant chemotherapy is not inferior to 6 months in colorecal cancer Iveson T et al. J Clin Onc 2017; 35 suppl, Abstr 3502)
8/12/2017: Two trials demonstrated early Abiraterone intervention benefited prostate cancer (Fizazi K et al. ASCO Ann Meeting. Abstr LBA3; James N et al ASCO Ann Meeting. 2017; Abstr LBA5003)
8/6/2017: Pembrolizumab and chemotherapy as neoadjuvant therapy in breast cancer (http://investors.merck.com/news/press-release-details/2017/New-Data-From-Phase-2-I-SPY-2-TRIAL-Shows-Improved-Outcomes-with-Combination-of-Mercks-KEYTRUDA-pembrolizumab-Plus-Standard-Neoadjuvant-Therapy-in-Patients-with-High-Risk-Breast-Cancer/default.aspx)
8/5/2017: Intratumoral injection of plasmid/lymphokine-12 enhances melanoma response to pembrolizumab (Algazi a et al. ASCO-SITC Clin Immuuno-Oncol Symposium abstr 78)
7/30/2017: Clinical trial shows persistent complete response in recurrent/refractory diffuse large B-cell lymphoma (Schuster S et al. Intl Conf Malig Lymphoma, Switzerland 2017 abstr 007)
7/29/2017: Wound complication after breast reconstruction in relation to timing and types of implants following mastectomy (Olsen MA et al. JAMA Surg 2017 )
7/23/2017: Statin criteria may help to identify high-risk cancer group (Pursnani A et al. J Clin Onc 2017, July 12. http://newsroom.heart.org/news/acc-aha-publish-new-guideline-for-management-of-blood-cholesterol )
7/22/2017: Dark hair dye and chemical relaxers linked to breast cancer risk (Adana, AM, et. Carcinogenesis 2017 June 9. https://doi.org/10.1093/carcin/bgx060)
7/16/2017: Novel tropomyosin receptor kinase inhibitor produces unexpected response across different tumor types (Hyman DM et al. ASCO 2017, abstr LBA250)
7/15/2017: Olaparib improves progression-free survival in BRCA-associated breast cancer (Robson, ME et al. N Engl J Med 2017; doi: 10.1056/NEJMoa1706450 )
7/9/2017: Hydroxychloroquine enhances antitumor activity of neoadjuvant chemotherapy in pancreatic cancer (MIller-Ocuin JL et al. Society of Surg Onc Ann Cancer Symposium. 2017; Abstr 3)
7/8/2017: Avoid surgery after neoadjuvant therapy for breast cancer (Tadros AB et al. JAMA Surg 2017 doi: 10.1001/jamasurg.2017.0562)
7/2/2017: Atezolizumab improves survival in comparison with docetaxel in previously treated NSCLC (Rittmeyer A et al Lancet 2017; 389: 255-65)
7/1/2017: Radiation and anti-androgen therapy prolonged survival among relapsed prostate cancer patients (Shipley WU et al. N Engl J Med 2017; 376:417-28)
6/24/2017: Different response and prognosis in right and left colon cancer (Tejpar S et al JAMA Onc 2016; Oct. 10; Siena S et al Ann Oncol 2016; 27（supp_6）485p; Heinemann V et al Lancet Onc 2014; 15: 1065-75; Venook AP et al J Clin Onc 2014; 32（18）; Sartorial-Bianchi A et al.Lancet Onc 2016: 17: 738-46′ Hurwitz H et al J Clin Onc 2017; 35 （No. 4 Suppl）：656)
6/18/2017: Adding a second antibody to block HER-2 may lower breast cancer recurrence (Von Winckwitz G et al ASCO Ann Meeting 2017; abstr LBA500)
6/17/2017: Stress granules in pancreatic cancer and drug resistance (Grabocka E & Bar-Sagi D. Cell 2016; 167:1803-13.)
6/11/2017: Modest long-term survival with check-point inhibitors in non-small cell lung cancer (J Brahmer et al. 2017 AACR Annual Meeting. Abstr CT077)
6/10/2017: Prognostic value of plasma circulating DNA in pancreatic cancer patients (Pietrasz E et al. Clin Caner Res 2016; doi: 10.1158/1078-0432.CCR-16-0806)
6/4/2017: Adjuvant capecitabine for biliary tract cancer improves overall survival (Primose JN et al. ASCO Annual Meeting 2017. abstr 4006)
6/3/2017: Japanese phase III Trial of alectinib vs crizotinib in ALK-positive NSCLC (Hida T et al. Lancet 2017; DOI: http://dx.doi.org/10.1016/S0140-6736(17)30565-2)
5/28/2017: Atezolizumab benefited triple-negative breast cancer patients who obtained objective response (Schmid P et al AACR 2017 abstr 2986)
5/27/2017: New imaging method may predict immunotherapy response early (Larimer BM et al. Cancer Res 2017; 2318-27)
5/21/2017: Is Cabozantinib a standard of care for advanced renal cell cancer? (Schmidinger M reported at 2017 Eur Cancer Congress. Abstr 2117.)
5/20/2017: Newfound signal helps pancreatic cancer cells hide from immune system (Daley D et al. Nature Medicine 2017:\; doi:10.1038/nm.4314)
5/14/2017: Non-engineered T cell therapy produces durable responses in hematologic malignancies (Leen AM. presented at 2017 ASCO-SITC Clinical Immuno-Oncology Syposium)
5/13/2017: Heme iron and nitrate additives implicated early death in population-based study (Etemadi A et al BMJ 2017; DOI: 10.1136/bmj.j1957 May 11 2017)
5/7/2017: Gut bacteria may enhance, or hamper, response to anti-PD-1 agents (Gopalakrishnan V et al ASCO-STTC Clin Immun-Oncol Sumposium. 2017; abstr 02)
5/6/2017: A Multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer (O’Shaughnessy MJ et al Urol 2017:102:164-72)
4/30/2017: Ki67 as tool for neoadjuvant chemotherapy decision in ER-positive breast cancer patients (Ellis MJ et al J Clin Onc 2017; 35: 1061-9)
4/29/2017: Inhibiting histone deacetylase to reverse resistance to angiogenesis inhibitors (Aggarwal R et al J Clin Onc 2017; 35:1231-9)
4/23/2017: Predictor of pathological complete response following trastuzumab and lapatinib in early-stage HER2-positive breast cancer (PAMELA)(Llombart-Cussac A et al Lancet Oncol 2017; 18:545-54)
4/22/2017: Early phase report of combination treatment with HPV vaccine and chemotherapy in advanced cervical cancer (Melief CJ et al 2017 ASCO0SITC Clinical Immuno-Oncology Symposium. abstr 140)
4/16/2017: ASCO Updates Potentially Curable Pancreatic Cancer Guideline (Khorana AA et al. J Clin Oncol. 2017 Apr 11. doi: 10.1200/JCO.2017.72.4948)
4/15/2017: Final Results of European Intergroup Trial of Early PET-Adapted Treatment in Hodgkin Lymphoma (André MPE et al J Clin Onc 2017; published April 6. DOI: 10.1200/JCO.2016.68.6394 Journal of Clinical Oncology)
4/9/2017: Immunotherapy may hasten tumor growth in some patients (Kato S et al Clin Cancer Res 2017; March 28. doi: 10.1158/1078-0432.CCR-16-3133)
4/8/2017: Chemoimmunotherapy regimen safe and active in pancreatic cancer (Wainberg ZA J Clin Oncol 2017; 35（suppl 4 S, anstr 412）)
4/2/2017: Results from MONALLESA-2: Are all CDK4/6 inhibitors equal? (Hoortobagyi GN e al N Engl J Med 2016; 375:1738-48. Cristofanilli M et al Lancet Oncol 2016: 17:425-39. Patnaik A et al Cancer Discov 2016; 6: 740-53. Finn RS et al N Engl J Med 2016; 375: 1925-6. )
4/1/2017: Brentuximab vedotin beats standard of care for cutaneous T-cell lymphoma (Kim YH et al ASH 2016 abstr 182)
3/26/2017: A combo of pembrolizumab and ramucirumab is active for advanced gastric and GE junction cancer (Chau I et al J Clin Oncol 2017; 35: suppl 4S; abstr 102)
3/25/2017: Rare complications of checkpoint inhibitors to the heart (Johnson DB et al N Engl J Med 2016; 375: 1749-55. Chang F et al Trends Immunol 2017; 38: 77-8. Heinzerling L et al J Immunolther Cancer 2016; 4: 50)
3/18/2017 : Bisphosphate used in adjuvant setting for breast cancer: ASCO guideline (Dhesy-Thind, S et al. J Clin Onc. 2017 published in print March 6)
3/12/2017: Anti-BCMA CAR-T-cell therapy approaches 80% response rate in multiple myeloma (Berdeja J Lin et al 2016 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Abstr 14LBA)
3/11/2017: Trial of Quisinostat in ovarian cancer meets primary endpoints (HemOnc Today 2017; 18 : 55)
3/5/2017: Pembrolizumab vs chemotherapy in second-line treatment of advanced urothelial carcinoma (Bellmunt et al N Engl J Med 2017 February 17, DOI: 10.1056/NEJMoa1613683)
3/4/2017: First look at combo with immunotherapy in untreated metastatic renal cell carcinoma (Powles T et al 2017 Genitourinary Cancers Symposium (GUCS) Abstr 431)
2/26/2017: Dual Inhibition proves effective for BRAF-mutated colorectal tumors (Kopetz S et al 2017 Gastrointestinal Cancer Symposium. Abstr 520)
2/25/2017 Results for Veliparib regimen in BRCA+ breast cancer (Han RS et al 2016 San Antonia Breast Cancer Symposium. Abstr S2-05)
2/19/2017 : KTE-C19 shows impressive responses in aggressive lymphomas (Neelapu SS et al 58th ASH Annual Meeting and Exposition 2016 Abstr LBA6; Locke FL et al 58th ASH Annual Meeting and Exposition 2016 Abstr 998; Crump M J Clin Oncol 2016; 34 （suppl; abstr 7516)
2/18/2017: Padeliporfin vascular-targeted photodynamic therapy for low grade prostate cancer (A-R Azzouzi et al Lancet Onc 2017; 18: 181–191)
2/12/2017: Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone (Hortobagyi GN et al JAMA Oncol January 26, 2017. doi:10.1001/jamaoncol.2016.6316)
2/11/2017: Novel antibody-drug conjugate targets triple-negative breast cancer (Bardia A et al 2016 San Antonia Breast Cancer Symposium. Abs P4-22-15)
2/5/2017: NSCLC: Etoposide/cisplatin may be superior to carboplatin/paclitaxel with radiation (Liang J, et al. Ann Oncol. 2017 Jan 30. doi: 10.1093/annonc/mdx009 . Santana-Davila R et al J Clin Onc 2015; 33: 567-74)
2/4/2017: Breathing test may diagnose esophageal and gastric cancer (European CanCer Organisation (ECCO) Congress 2017. Abstract 6LBA, Sheraz Markar presented January 30, 2017)
1/29/2017: Extended endocrine therapy for breast cancer (Mamoumas EP et al. 2016 San Antonio Breast cancer Symphsium. Abs. S1-05)
1/28/2017: NSCLC assay predicts node status, early recurrence (Intl Asso Study Lung Cancer Multidisciplinary Symp Thor Onc 2016 Chicago)
1/22/17: Vantictumab combination benefits stage 4 pancreatic cancer (Weeks, C presented at ESMO [Eur Soc Med Onc] Congress 2016)
1/21/2017: Radiation-TGF-β inhibition combo elicits activity in metastatic breast cancer (Gate D et al Proc Natl Acad Sci USA 2014; 111: E3458-66. Schafer D 2016 ASTRO Meeting)
1/15/2017: Urine gene expression assay may improve the diagnosis of high-grade prostate cancer (McKieman J et al JAMA Oncol 2016; doi:10.1001/jamaoncol.2016.0097; Patel HD et al JAMA Oncol 2016; doi:101001/jamaoncol.2016.0170)
1/14/2017: Addition of capecitabine to adjuvant chemotherapy extends survival in pancreatic cancer (Neoptolemos JE et al ASCO，2016，Abstract LBA4006)
1/8/2017: Cancer death in America continues to drop (Siegel RL et al. CA A Cancer J Clin 2017 DOI:10.3322/caac.21387)
1/7/2017: Arginine deprivation shows promise for malignant pleural mesothelioma (Szlosarek PW et al JAMO Oncol2016;10.1001/jamaoncol.2016.3049)
1/1/2017: Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer (Nishino M et al. JAMA Onc 2016; 2: 1607-1616)